Filing Details

Accession Number:
0001441557-17-000004
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2017-01-06 17:53:51
Reporting Period:
2016-12-18
Filing Date:
2017-01-06
Accepted Time:
2017-01-06 17:53:51
Original Submission Date:
2017-01-04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1187953 Creative Medical Technology Holdings Inc. CELZ Biological Products, (No Disgnostic Substances) (2836) 870622284
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1674492 Timothy Warbington 2017 W Peoria Ave
Phoenix AZ 85029
President & Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-12-18 3,412,791 $0.01 61,553,876 No 4 S Indirect Entity
Common Stock Disposition 2016-12-31 2,935,609 $0.10 58,618,267 No 4 S Indirect Entity
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Entity
No 4 S Indirect Entity
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,466,667 Direct
Common Stock 64,966,667 Indirect Entity
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Warrants $0.10 2016-09-30 2026-09-30 30,000 30,000 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2026-09-30 30,000 30,000 Indirect
Footnotes
  1. Shares are held by Creative Medical Health, of which Mr. Warbington is President. Mr. Warbington disclaims beneficial ownership of such shares of common stock except to the extent of his pecuniary interest therein.
  2. Warrants are held by Creative Medical Health, of which Mr. Warbington is President. Mr. Warbington disclaims beneficial ownership of such shares of common stock except to the extent of his pecuniary interest therein.
  3. The transaction reported hereby represents a cancellation of debt owed by the reporting party to the purchaser. The total amount of debt exchanged for the common shares was $293,560.91, or $0.10 per share, the same price as shares of common stock purchased by the reporting party on September 30, 2016. As an incentive to enter into the transaction the reporting party granted to the purchaser an option to purchase up to 293,561 shares of the Issuer at $0.10 per share with such option expiring August 1, 2019.